EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Amicogen Inc (092040) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Amicogen Inc KRW 791, price KRW 988, upside -19.9%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7092040005

AI Thin data Oct 3, 2026

Amicogen Inc

092040 · KQ

Weak valuationQuality is weak on top of the rich price.

Moderate debt
Fair value 791.11 KRW · Overvalued (−19.9%)
Quality 26/100
Weak Growth (revenue 5y −18.4 %/yr in KRW)
Loss-making · -10.5% net margin (TTM)
Negative free cash flow
Trails peers (1/8)
Narrow moat 5/100
Thin data
Watch Amicogen Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

20,964 KRW 822.00 KRW Fair Value 791.11 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 822.00 KRW – 20,964 KRW · fair‑value band 590.38 KRW – 1,181 KRW · the 988.00 KRW price screens above the 791.11 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Amicogen in your weekly email

Every Wednesday you see whether Amicogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food.

Show more

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company offers oral incurable and rare disease treatments, as well as manufactures and sells of pharmaceutical raw materials, animal drugs, human drugs, etc. The company was incorporated in 2000 and is headquartered in Jinju-Si, South Korea.

Stock analysis

Amicogen Inc (092040) currently trades at 988.00 KRW, while our model-based Fair Value estimate is 791.11 KRW, 19.9% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 590.38 KRW (bear) to 1,181 KRW (bull), the price of 988.00 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Amicogen Inc reported revenue of 42.0B KRW in FY2025 versus 125B KRW in FY2021, a compound −23.9%/yr. Reported net income was −30.0B KRW in FY2025.

Key figures

Market cap 82.4B KRW (≈ $61.3M) · P/S ratio 1.90 · Net margin −71.4% · Return on equity −4.0% · Return on assets (EBIT) −2.9% · Operating margin −26.0% · Revenue (TTM) 43.4B KRW · Revenue growth (YoY) +13.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 74% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −20%, 092040 screens richer than that median.

Fair Value models

Bear 590.38 KRW Fair Value 791.11 KRW Bull 1,181 KRW
Price 988.00 KRW · Upside -19.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 671.13 KRW 899.32 KRW 1,342 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 671.13 KRW 899.32 KRW 1,342 KRW 54

Open the full fair value analysis →

Notify me when 092040 reaches fair value

Put 092040 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 26/100

Of which business quality 26 · Market factors (momentum, volatility) 16

Profitability 1
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 29
Balance sheet, leverage, solvency risk
Investment 87
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 36
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−75.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−33.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.4%
Start year 2020 (pandemic). Over 10 years: +2.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.4% (2020) → −36.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

092040 screens overvalued: fair value 20% below the price. Compare with Merck KGaA →

Compare Amicogen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −19.9% · Below median
Profitability
Return on assets −4.2% · Bottom 25%
Net margin (TTM) −10.5% · Bottom 25%
Operating margin (TTM) −26.0% · Bottom 25%
Growth and dividend
Revenue growth 13.5% · Above median
Balance sheet
Debt / equity 0.57× · Highest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 17
FUTURE (revenue growth)68 · sector 24
PAST (return on equity)0 · sector 27
HEALTH (low debt)72 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amicogen Inc · Fair Value
791.11 KRW −20%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Amicogen Inc Fair Value". https://www.fairvalue-calculator.com/stock/092040

Frequently asked questions

Is Amicogen Inc (092040) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 791.11 KRW versus a price of 988.00 KRW, about −20% upside (overvalued).
What is the fair value of 092040?
Our model-based fair value for Amicogen Inc is 791.11 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 988.00 KRW.
What is the quality score of 092040?
Amicogen Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amicogen Inc (092040)?
Our model-based price target is the fair value of 791.11 KRW (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 590.38 KRW, optimistic scenario 1,181 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Amicogen Inc stock forecast for 2026?
Our models put fair value at 791.11 KRW, about −20% upside versus a price of 988.00 KRW (overvalued). Cautious scenario 590.38 KRW, optimistic scenario 1,181 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Amicogen Inc (092040)?
Amicogen Inc reported trailing-twelve-month revenue of about 43.4B KRW (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Amicogen Inc (092040)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amicogen Inc it is 791.11 KRW per share (as of Oct 3, 2026), against a price of 988.00 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Amicogen Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 092040 trades above its calculated fair value: price 988.00 KRW, fair value 791.11 KRW, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 092040?
No. The price is what the market pays today (988.00 KRW); the fair value is what the company's own numbers justify (791.11 KRW). For Amicogen Inc the two are 196.89 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Amicogen Inc worth?
The market values Amicogen Inc at about 82.4B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 988.00 KRW; our models calculate a fair value of 791.11 KRW per share.
What do the bullish and bearish scenarios say about 092040?
Our models span a range for Amicogen Inc: cautious scenario 590.38 KRW, base 791.11 KRW, optimistic 1,181 KRW per share (as of Oct 3, 2026, price 988.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Amicogen Inc (092040)?
Balance-sheet figures for Amicogen Inc (as of Oct 3, 2026): return on equity −4.0%, debt of 0.57 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 092040 from its 52-week high?
Amicogen Inc trades at 988.00 KRW, about 74% below its 52-week high of 3,860 KRW and 20% above the low of 822.00 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 791.11 KRW is for.
Which stocks are comparable to Amicogen Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amicogen Inc stock attractive at the current price?
The data as of Oct 3, 2026: price 988.00 KRW, calculated fair value 791.11 KRW (−20%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 092040 calculated?
We run Amicogen Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 791.11 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Amicogen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amicogen Inc (092040)?
The closing price on Oct 2, 2026 was 988.00 KRW. Our model-based fair value is 791.11 KRW, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amicogen Inc right now?
Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (590.38 KRW to 1,181 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Amicogen Inc

How large is the market capitalisation of Amicogen Inc (092040)?
The market capitalisation of Amicogen Inc is 82.4B KRW (≈ $61.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amicogen Inc (092040)?
The price-to-sales ratio of Amicogen Inc is 1.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Amicogen Inc (092040)?
The net margin of Amicogen Inc is −71.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amicogen Inc (092040)?
The return on equity (ROE) of Amicogen Inc is −4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amicogen Inc (092040)?
On an EBIT basis the return on assets of Amicogen Inc is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amicogen Inc (092040)?
The operating margin of Amicogen Inc is −26.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amicogen Inc (092040)?
Revenue at Amicogen Inc is growing +13.5% versus a year earlier (3y avg −33.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amicogen Inc (092040)?
Earnings per share at Amicogen Inc are growing −16.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Amicogen Inc (092040) generate?
The free cash flow of Amicogen Inc is −28.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Amicogen Inc (092040) carry?
The net debt of Amicogen Inc is 86.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Amicogen Inc in the live analysis

One click puts Amicogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.